Goldman Sachs’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.19B | Buy |
18,891,624
+2,312,707
| +14% | +$185M | 0.14% | 133 |
|
|
2025
Q4 | $1.58B | Buy |
16,578,917
+1,573,658
| +10% | +$154M | 0.19% | 86 |
|
|
2025
Q3 | $1.46B | Buy |
15,005,259
+1,070,278
| +8% | +$111M | 0.18% | 90 |
|
|
2025
Q2 | $1.5B | Buy |
13,934,981
+5,149
| +0% | +$521K | 0.2% | 77 |
|
|
2025
Q1 | $1.41B | Buy |
13,929,832
+1,044,524
| +8% | +$105M | 0.23% | 63 |
|
|
2024
Q4 | $1.15B | Sell |
12,885,308
-357,229
| -3% | -$31.4M | 0.18% | 89 |
|
|
2024
Q3 | $1.11B | Sell |
13,242,537
-186,272
| -1% | -$14.7M | 0.18% | 97 |
|
|
2024
Q2 | $1.03B | Sell |
13,428,809
-1,237,659
| -8% | -$90.6M | 0.17% | 101 |
|
|
2024
Q1 | $1B | Sell |
14,666,468
-1,360,025
| -8% | -$87.4M | 0.18% | 103 |
|
|
2023
Q4 | $926M | Sell |
16,026,493
-591,845
| -4% | -$31.6M | 0.17% | 100 |
|
|
2023
Q3 | $877M | Sell |
16,618,338
-2,152,877
| -11% | -$113M | 0.19% | 96 |
|
|
2023
Q2 | $1.02B | Buy |
18,771,215
+897,259
| +5% | +$46.9M | 0.22% | 72 |
|
|
2023
Q1 | $894M | Sell |
17,873,956
-86,573
| -0.5% | -$4.08M | 0.21% | 80 |
|
|
2022
Q4 | $831M | Sell |
17,960,529
-1,504,520
| -8% | -$65.1M | 0.2% | 80 |
|
|
2022
Q3 | $754M | Buy |
19,465,049
+5,062,939
| +35% | +$203M | 0.19% | 87 |
|
|
2022
Q2 | $537M | Sell |
14,402,110
-3,443,340
| -19% | -$140M | 0.13% | 117 |
|
|
2022
Q1 | $790M | Sell |
17,845,450
-1,110,661
| -6% | -$48.1M | 0.17% | 95 |
|
|
2021
Q4 | $805M | Buy |
18,956,111
+2,669,063
| +16% | +$112M | 0.16% | 103 |
|
|
2021
Q3 | $707M | Buy |
16,287,048
+885,503
| +6% | +$39.2M | 0.15% | 117 |
|
|
2021
Q2 | $659M | Sell |
15,401,545
-1,188,807
| -7% | -$50M | 0.15% | 118 |
|
|
2021
Q1 | $641M | Buy |
16,590,352
+1,950,892
| +13% | +$73.8M | 0.16% | 102 |
|
|
2020
Q4 | $526M | Buy |
14,639,460
+1,619,967
| +12% | +$58.4M | 0.14% | 128 |
|
|
2020
Q3 | $497M | Sell |
13,019,493
-1,138,244
| -8% | -$43.9M | 0.14% | 130 |
|
|
2020
Q2 | $497M | Buy |
14,157,737
+182,943
| +1% | +$6.59M | 0.15% | 121 |
|
|
2020
Q1 | $456M | Sell |
13,974,794
-690,962
| -5% | -$27M | 0.16% | 111 |
|
|
2019
Q4 | $663M | Buy |
14,665,756
+1,325,017
| +10% | +$55.4M | 0.17% | 110 |
|
|
2019
Q3 | $543M | Buy |
13,340,739
+567,189
| +4% | +$24M | 0.16% | 113 |
|
|
2019
Q2 | $549M | Buy |
12,773,550
+441,275
| +4% | +$17M | 0.16% | 113 |
|
|
2019
Q1 | $473M | Sell |
12,332,275
-1,545,680
| -11% | -$59M | 0.14% | 117 |
|
|
2018
Q4 | $490M | Sell |
13,877,955
-1,854,595
| -12% | -$67.3M | 0.16% | 102 |
|
|
2018
Q3 | $606M | Sell |
15,732,550
-4,828,750
| -23% | -$169M | 0.16% | 105 |
|
|
2018
Q2 | $672M | Buy |
20,561,300
+1,751,488
| +9% | +$52.8M | 0.18% | 87 |
|
|
2018
Q1 | $514M | Buy |
18,809,812
+6,146,291
| +49% | +$167M | 0.13% | 155 |
|
|
2017
Q4 | $314M | Buy |
12,663,521
+4,219,434
| +50% | +$116M | 0.08% | 282 |
|
|
2017
Q3 | $246M | Buy |
8,444,087
+1,106,056
| +15% | +$30.5M | 0.06% | 343 |
|
|
2017
Q2 | $203M | Buy |
7,338,031
+1,752,426
| +31% | +$46.5M | 0.05% | 398 |
|
|
2017
Q1 | $139M | Buy |
5,585,605
+276,013
| +5% | +$6.71M | 0.04% | 548 |
|
|
2016
Q4 | $115M | Sell |
5,309,592
-300,290
| -5% | -$6.55M | 0.03% | 687 |
|
|
2016
Q3 | $134M | Sell |
5,609,882
-977,484
| -15% | -$23.3M | 0.04% | 558 |
|
|
2016
Q2 | $154M | Buy |
6,587,366
+2,960,198
| +82% | +$64M | 0.05% | 452 |
|
|
2016
Q1 | $68.2M | Sell |
3,627,168
-1,225,878
| -25% | -$21.5M | 0.02% | 868 |
|
|
2015
Q4 | $89.5M | Buy |
4,853,046
+2,868,278
| +145% | +$51.4M | 0.03% | 733 |
|
|
2015
Q3 | $32.6M | Sell |
1,984,768
-2,938,044
| -60% | -$50.2M | 0.01% | 1355 |
|
|
2015
Q2 | $87.1M | Buy |
4,922,812
+1,467,272
| +42% | +$26.2M | 0.03% | 745 |
|
|
2015
Q1 | $61.3M | Sell |
3,455,540
-2,359,112
| -41% | -$37.3M | 0.02% | 948 |
|
|
2014
Q4 | $77M | Buy |
5,814,652
+2,380,459
| +69% | +$30.4M | 0.02% | 816 |
|
|
2014
Q3 | $40.6M | Sell |
3,434,193
-2,937,813
| -46% | -$37M | 0.01% | 1230 |
|
|
2014
Q2 | $81.4M | Buy |
6,372,006
+388,440
| +6% | +$5.05M | 0.03% | 784 |
|
|
2014
Q1 | $80.9M | Sell |
5,983,566
-11,306,817
| -65% | -$148M | 0.03% | 718 |
|
|
2013
Q4 | $208M | Sell |
17,290,383
-3,213,934
| -16% | -$38M | 0.07% | 322 |
|
|
2013
Q3 | $241M | Sell |
20,504,317
-715,045
| -3% | -$7.73M | 0.09% | 231 |
|
|
2013
Q2 | $197M | Buy |
+21,219,362
| New | +$180M | 0.08% | 281 |
|
Other funds holding BSX
VCM
VPM
Goldman Sachs's BSX Position: Q1 2026 in Review
Goldman Sachs increased its Boston Scientific (BSX) stake by 14% in Q1 2026, buying an estimated $185M and bringing the position to 18,891,624 shares worth $1.19B. The position accounts for 0.14% of the portfolio, ranked #133.
Goldman Sachs first reported a position in BSX in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.58B in Q4 2025. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.
- Goldman Sachs held 18,891,624 shares of Boston Scientific worth $1.19B as of Q1 2026.
- Goldman Sachs bought 2,312,707 Boston Scientific shares in Q1 2026, an estimated $185M.
- Boston Scientific made up 0.14% of Goldman Sachs's portfolio in Q1 2026, its #133 holding.
- Goldman Sachs first reported a position in Boston Scientific in Q2 2013 and has held it in 52 quarters since.
- Goldman Sachs's Boston Scientific position peaked at $1.58B in Q4 2025.
- 1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.